TAK
Takeda PharmaceuticalCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case: Successful clinical readouts, clearer post-quarter guidance, and tangible cost-synergy realization drive re-rating toward the analyst high (19.5). Stronger-than-expected launch execution or an accretive licensing/M&A outcome would add incremental upside.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.5.
What can break
Failure to deliver integration synergies or cost savings
Momentum
28
Value
66
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $19.50 · Bear $14.87
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-30 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.34
Why
Momentum28 · Δ7d -2.6
Value66 · Δ7d +0.5
Sentiment61 · Δ7d +10.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
28
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
+9.2
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.9
Sentiment
61
33% active weight
Current posture
7d trendImproving
Δ7d
+10.8
Δ21d
+16.4
Why this grade
Composite grade C. Momentum 28.3 / Value 65.7 / Sentiment 61.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$48.47B
Beta
0.05
Shares Out
1.58B
P/E (TTM)
226.9
P/S (TTM)
1.77
P/FCF (TTM)
12.72
Rev YoY
-5.4%
EPS YoY
-113.1%
Gross Margin
+64.6%
Op Margin
+5.6%
Net Debt
$27B
Current Ratio
1.36
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology